摘要
目的:观察乌拉地尔、硝普钠治疗高血压急症的降压效果及安全性。方法:86例高血压急症患者被随机分成:乌拉地尔组(43例),持续静脉泵入乌拉地尔;硝普钠组(43例),持续静脉泵入硝普钠作为对照。监测两组血压,观察治疗效果,同时了解达到治疗高血压急症的最初目标的安全性。结果:乌拉地尔、硝普钠组在用药前血压无显著差异[(219.21±27.92)/(148.79±14.15)mmHg比(226.98±23.00)/(148.03±11.49)mmHg,P>0.05];两组在用药5min后血压开始明显下降,用药后各时间段血压均较治疗前明显下降,(P<0.01),于用药后360min乌拉地尔、硝普钠组血压分别降至[(143.53±11.16)/(89.56±8.01)mmHg]、[(143.88±8.09)mmHg/(90.16±6.44)mmHg],两种药物疗效差异无显著性(P>0.05),都能达到治疗的最初目标。乌拉地尔、硝普钠组用药前心率无显著差异[(98.28±11.52)次/min比(98.09±9.23)次/min],于用药后360min乌拉地尔组心率显著降至(96.95±11.37)次/min,而硝普钠组心率却显著上升至(100.33±10.96)次/min,乌拉地尔组对心率影响显著优于硝普钠组(P<0.05)。结论:乌拉地尔对高血压急症有显著疗效,安全性高,值得推广。
Objective： To observe antihypertensive effect and safety of urapidil and sodium nitroprusside in treatment of hypertensive urgency. Methods： A total of 86 patients with hypertensive urgency were randomly divided into ura- pidil group （n= 43, received urapidil through venous pump） and sodium nitroprusside group （n= 43, received sodium nitroprusside through venous pump as control）. Blood pressure and therapeutic effects were monitored and observed in the two groups, and safety of reaching initial goal of treatment of hypertensive urgency was also investigated. Resuits.. Before therapy the blood pressures of urapidil group and sodium nitroprusside group were no significant difference [（219. 21±27. 92） / （148.79±14.15） mmHgvs. （226.98±23.00） / （148.03±11.49） mmHg, P〈0.05] after administer 5 min, blood pressures significantly decreased in the two groups, and blood pressure of each time segment was significantly lower than before treatment （P〈0.01）, after administer 360 min the blood pressures of urapidil group and sodium nitroprusside group respectively decreased to [ （143.53±11.16） / （89.56±8.01） mm Hg], [ （143.88±8.09） mmHg / （90.16±6.44） mmHg] ; there was no significant difference in therapeutic effect between the two drugs （P〉0. 05）, both of them can reach initial goal of treatment. Before therapy the heart rate （HR） of urapidil group and sodium nitroprusside group were no significant difference [ （98.28± 11.52） times/min vs. （98.09±9.23） times/mini, after administer 360 min HR of urapidil group decreased to （96.95±11.37） times/min, but HR of sodium nitroprusside group increased to （100.33± 10.96） times/min , urapidil group was better than sodium nitroprusside group in lowering heart rate （P〈0.05）. Conclusion： Urapidil has remarkable therapeutic effect on hypertensive urgency, and possesses high safety, should be promoted in clinic.
出处
《心血管康复医学杂志》
CAS
2011年第6期583-585,共3页
Chinese Journal of Cardiovascular Rehabilitation Medicine
关键词
高血压
乌拉地尔
硝普钠
Hypertension
Urapidil
Nitroprusside
